BioSpace News Archive

Strategic Partners Will Benefit from Complementary Strengths; Confirm BioSciences to Continue Operating Under Its Current Name

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from FLEX, the large-scale, prospective, observational breast cancer study, has been selected for presentation in six posters during the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).

Studies Showed Hospitals Effectively Reduced Both the Incidence of and Evaluations for Late-Onset Sepsis When Prolacta’s Fortifiers Were Used in Lieu of Cow Milk-Based Fortifiers

- $60 million upfront, including a $10 million equity investment, $65 million at FDA’s acceptance of NDA for maralixibat for ALGS, $35 million upon FDA approval of maralixibat in ALGS, and up to $50 million to fund in-licensing and acquisitions - Funding agreement to support the commercialization of maralixibat for the treatment of cholestatic pruritus in patients with ALGS in the United States

‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) trial led by MD Anderson Cancer Center ‒ Kaplan Meier analysis of disease free survival for patients treated with GP2 immunotherapy shows 100% survival (0% breast cancer recurrences, p = 0.0

Web-based platform for fresh osteochondral allograft ordering debuts this week during the virtual 2020 Orthopedic Summit and Emerging Technologies conference Dec. 10-12.

A new study published in the Journal of Investigative Dermatology (JID) found that VisualDx’s artificial intelligence solution, DermExpert™, analyzed skin conditions with the same degree of accuracy as primary care physicians (PCPs) referencing a visual aid.

- Pelareorep strongly increases CelTIL score, the primary endpoint and a measure of tumor cellularity and inflammation associated with favorable clinical outcomes - Pelareorep increased tumor PD-L1 expression 105-fold, thereby making the tumors more amenable to immuno-checkpoint inhibitor treatment

Volta Medical, a pioneering French-based HealthTech startup is pleased to announce that it has obtained FDA clearance for its revolutionary VX1 AI (artificial intelligence) software. This is the first FDA clearance for an AI based tool in interventional cardiac electrophysiology. VX1 is a machine and deep learning-based algorith

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of olinvacimab and pembrolizumab for metastatic triple-negative breast cancer (mTNBC) pat